CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 15, 2015, Pages 4725-4730

  Cheah, Ming T ^a,b   Chen, James Y ^a,b   Sahoo, Debashis ^a,b,c   Contreras Trujillo, Humberto ^a,b   Volkmer, Anne K ^a,b,d   Scheeren, Ferenc A ^e   Volkmer, Jens Peter ^a,b   Weissman, Irving L ^a,b  

^a Stanford California and Cofounder   (United States)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Bladder cancer; CD14; Inflammation; Microenvironment

Indexed keywords

AUTACOID; CD14 ANTIGEN; INTERLEUKIN 6; TOLL LIKE RECEPTOR; CYTOKERATIN 14; CYTOKINE; IL2RG PROTEIN, MOUSE; INTERLEUKIN 2 RECEPTOR GAMMA; KRT14 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BLADDER CANCER; BLADDER CANCER CELL LINE; BONE MARROW CELL; CANCER GROWTH; CELL DIVISION; CELL INFILTRATION; CELL PROLIFERATION; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; TUMOR VASCULARIZATION; ANIMAL; BLADDER TUMOR; C57BL MOUSE; CANCER TRANSPLANTATION; DEFICIENCY; DNA MICROARRAY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; TRANSGENIC MOUSE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIGENS, CD14; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; KERATIN-14; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR MICROENVIRONMENT; URINARY BLADDER NEOPLASMS;

EID: 84928139478     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1424795112     Document Type: Article

References (53)

1. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57-70.
2. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144(5):646-674.
3. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86(3):353-364.
4. Egeblad M, Nakasone ES, Werb Z (2010) Tumors as organs: Complex tissues that interface with the entire organism. Dev Cell 18(6):884-901.
5. Dirat B, Bochet L, Escourrou G, Valet P, Muller C (2010) Unraveling the obesity and breast cancer links: A role for cancer-associated adipocytes? Endocr Dev 19:45-52.
6. Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6(5):392-401.
7. Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell 141(1):52-67.
8. DeNardo DG, Andreu P, Coussens LM (2010) Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev 29(2):309-316.
9. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883-899.
10. Qian BZ, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141(1):39-51.
11. de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6(1):24-37.
12. Murdoch C, Muthana M, Coffelt SB, Lewis CE (2008) The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 8(8):618-631.
13. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23(11):549-555.
14. Sica A, Schioppa T, Mantovani A, Allavena P (2006) Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy. Eur J Cancer 42(6):717-727.
15. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436-444.
16. Johansson M, Denardo DG, Coussens LM (2008) Polarized immune responses differentially regulate cancer development. Immunol Rev 222:145-154.
17. Biswas SK, Mantovani A (2010) Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nat Immunol 11(10):889-896.
18. Fridlender ZG, Albelda SM (2012) Tumor-associated neutrophils: Friend or foe? Carcinogenesis 33(5):949-955.
19. Allavena P, Mantovani A (2012) Immunology in the clinic review series; Focus on cancer: Tumour-associated macrophages: Undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol 167(2):195-205.
20. Zumsteg A, Christofori G (2009) Corrupt policemen: Inflammatory cells promote tumor angiogenesis. Curr Opin Oncol 21(1):60-70.
21. De Palma M, Murdoch C, Venneri MA, Naldini L, Lewis CE (2007) Tie2-expressing monocytes: Regulation of tumor angiogenesis and therapeutic implications. Trends Immunol 28(12):519-524.
22. Gordon S, Martinez FO (2010) Alternative activation of macrophages: Mechanism and functions. Immunity 32(5):593-604.
23. Balkwill FR, Mantovani A (2012) Cancer-related inflammation: Common themes and therapeutic opportunities. Semin Cancer Biol 22(1):33-40.
24. Melnikova VO, Bar-Eli M (2006) Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8. Pigment Cell Res 19(5):395-405.
25. Cho RW, Clarke MF (2008) Recent advances in cancer stem cells. Curr Opin Genet Dev 18(1):48-53.
26. Kennedy KM, Dewhirst MW (2010) Tumor metabolism of lactate: The influence and therapeutic potential for MCT and CD147 regulation. Future Oncol 6(1):127-148.
27. Ishimoto T, et al. (2011) CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 19(3):387-400.
28. Chan KS, et al. (2009) Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA 106(33):14016-14021.
29. Lobo NA, Shimono Y, Qian D, Clarke MF (2007) The biology of cancer stem cells. Annu Rev Cell Dev Biol 23:675-699.
30. Eruslanov E, et al. (2012) Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer 130(5):1109-1119.
31. Michaud DS (2007) Chronic inflammation and bladder cancer. Urol Oncol 25(3):260-268.
32. Volkmer JP, et al. (2012) Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proc Natl Acad Sci USA 109(6):2078-2083.
33. Elliott AY, Bronson DL, Stein N, Fraley EE (1976) In vitro cultivation of epithelial cells derived from tumors of the human urinary tract. Cancer Res 36(2 Pt 1):365-369.
34. Lippitz BE (2013) Cytokine patterns in patients with cancer: A systematic review. Lancet Oncol 14(6):e218-e228.
35. Bünger S, Laubert T, Roblick UJ, Habermann JK (2011) Serum biomarkers for improved diagnostic of pancreatic cancer: A current overview. J Cancer Res Clin Oncol 137(3):375-389.
36. Chen F, Zhang G, Cao Y, Hessner MJ, See WA (2009) MB49 murine urothelial carcinoma: Molecular and phenotypic comparison to human cell lines as a model of the direct tumor response to bacillus Calmette-Guerin. J Urol 182(6):2932-2937.
37. Loskog A, et al. (2004) Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor microenvironment. J Immunol 172(11):7200-7205.
38. O'Donnell MA, et al. (2004) Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: Dose dependent tumor eradication and generation of protective immunity. J Urol 171(3):1330-1335.
39. Akashi-Takamura S, Miyake K (2008) TLR accessory molecules. Curr Opin Immunol 20(4):420-425.
40. Baumann CL, et al. (2010) CD14 is a coreceptor of Toll-like receptors 7 and 9. J Exp Med 207(12):2689-2701.
41. Umansky V, Sevko A (2013) Tumor microenvironment and myeloid-derived suppressor cells. Cancer Microenviron 6(2):169-177.
42. Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ (2013) The immunosuppressive tumour network: Myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 138(2):105-115.
43. Dvorak HF (1986) Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315(26):1650-1659.
44. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860-867.
45. Naugler WE, Karin M (2008) The wolf in sheep's clothing: The role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 14(3):109-119.
46. Bollrath J, et al. (2009) gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15(2):91-102.
47. Bencsáth M, Blaskovits A, Borvendég J (2003) Biomolecular cytokine therapy. Pathol Oncol Res 9(1):24-29.
48. Wang Y, et al. (2012) Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. Cytokine 59(2):228-236.
49. Wang Y, et al. (2012) Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion. Cytokine 59(1):145-155.
50. Tye H, et al. (2012) STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell 22(4):466-478.
51. Yang HZ, et al. (2009) Blocking TLR2 activity attenuates pulmonary metastases of tumor. PLoS ONE 4(8):e6520.
52. Huang B, et al. (2005) Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 65(12):5009-5014.
53. Shin K, et al. (2011) Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder. Nature 472(7341):110-114.